Clinical trials · New York
Sickle Cell Disease clinical trials in New York
We’re tracking 28 recruiting sickle cell disease studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06439082RecruitingPhase 3
Crizanlizumab for sickle cell pain crises
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
The Bronx, New YorkAges 12–100 - NCT06699849RecruitingPhase 2
CSL889 for sickle cell pain crisis
This trial tests a new medicine, CSL889, for people with sickle cell disease who are currently having a pain crisis (vaso-occlusive crisis). The goal is to see if it safely helps reduce the pain and speed recovery.
New York, New YorkAges 12 years+ - NCT06609226RecruitingPhase 3
Long-term safety study of etavopivat for sickle cell disease or thalassaemia
This study looks at the long-term safety and benefits of taking etavopivat for people with sickle cell disease or thalassaemia who have already been helped by it in a previous trial. It aims to see if staying on the treatment continues to be safe and effective.
Brooklyn, New YorkAges 2 years+ - NCT06612268RecruitingPhase 3
Testing etavopivat for sickle cell disease
This study tests an experimental pill called etavopivat for people with sickle cell disease who have had some pain crises in the past year. The goal is to see if it reduces these crisis episodes.
Brooklyn, New YorkAges 12 years+ - NCT07224360RecruitingPhase 2
Safety of a new drug for sickle cell pain
This study tests a new medicine called anumigilimab to see if it is safe for people with sickle cell disease. The study focuses on those who have had pain crises recently, to help manage and prevent them.
The Bronx, New YorkAges 18 years+ - NCT07187973RecruitingPhase 1
Study of DISC-3405 for people with sickle cell disease
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
New York, New YorkAges 18 years+ - NCT02675959RecruitingPhase 2
Transplant with defibrotide for sickle cell disease
This trial tests a stem cell transplant from a half-matched donor using a strong conditioning regimen and a drug called defibrotide to protect organs. It aims to cure sickle cell disease in patients who have had serious complications like stroke, chest syndrome, or frequent pain episodes.
Valhalla, New YorkAges 6 months–21 years - NCT03587272RecruitingPhase 2
Sibling bone marrow transplant to reduce treatment side effects
This study tests a way to do a bone marrow (stem cell) transplant from an HLA-matched sibling in children with sickle cell disease, aiming to lower the risk of serious side effects. You may be considered if you have certain past sickle complications and your body can safely handle the transplant plan.
New York, New YorkAges 2–25 - NCT04099966RecruitingPhase 2
Stem cell transplant to treat high-risk blood cancers
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
Valhalla, New YorkAges 1 day–30 years - NCT05477563RecruitingPhase 3
One-time gene therapy for severe sickle cell and transfusion anemia
This trial tests a single dose of gene therapy (CTX001) to improve outcomes for people with severe sickle cell disease or transfusion-dependent beta-thalassemia. It aims to see how well it works and whether it is safe, especially after a planned stem cell transplant process.
New York, New YorkAges 12–35 - NCT05519111RecruitingPhase 2
Cannabinoid treatment to lower inflammation and sickle pain
This Phase 2 study tests a cannabinoid medicine (dronabinol) to reduce inflammation and pain related to sickle cell disease. It may help you have less pain that interferes with daily life if you meet the study requirements and can safely avoid cannabis during the study.
New York, New YorkAges 18 years+ - NCT05736419RecruitingPhase 2
Immune-suppressing treatment before stem cell transplant for blood disorders
This Phase 2 study tests an immune-suppressing treatment for people with sickle cell disease or beta-thalassemia who are preparing for a stem cell transplant from a donor. It aims to help the transplant work better by changing the immune response.
Commack, New YorkAges 2–50 - NCT06374238Recruiting
Peer Support for Young People with Sickle Cell Pain
This study is testing a peer support program for teens and young adults (ages 16–30) with sickle cell disease who have chronic pain. You'll connect with a trained peer supporter through your smartphone to learn pain coping skills and get support.
New York, New YorkAges 16–30 - NCT06930703RecruitingPhase 1/Phase 2
CBD for sickle cell pain
This trial tests if cannabidiol (CBD) can help reduce pain interference in adults with sickle cell disease. You will take CBD daily for 4 weeks and report your pain levels.
Manhattan, New YorkAges 18 years+ - NCT06941389Recruiting
Comparing stem cell transplant vs standard therapy for sickle cell disease
This study compares two treatment approaches for children with sickle cell anemia: a stem cell transplant from a matched family donor versus continuing regular disease-modifying medicines. It aims to see which treatment works better over time.
New York, New YorkAges 3–20 - NCT06975865RecruitingPhase 3
Rilzabrutinib for sickle-cell disease pain episodes
This study tests an oral medicine called rilzabrutinib to see if it can reduce painful episodes in people with sickle-cell disease. It may be an option if you have regular pain crises and are looking for a new treatment.
Staten Island, New YorkAges 10–65 - NCT07015684RecruitingPhase 1
Radioactive antibody and transplant for advanced sickle cell disease
This trial tests a radioactive antibody (131I-apamistamab) as part of conditioning before a stem cell transplant from a matched sibling donor. It aims to make the transplant safer and more effective for people with severe sickle cell disease.
New York, New YorkAges 12–50 - NCT04819841RecruitingPhase 1/Phase 2
Gene correction using your own stem cells to improve sickle disease
This trial tests a gene-correction treatment that changes sickle hemoglobin (HbS) into normal hemoglobin (HbA) using your own stem cells. It may help reduce severe sickle cell complications for people with severe disease who meet specific safety and medical criteria.
New York, New YorkAges 12–50 - NCT06363760Enrolling by invitation
Long-term follow-up after EDIT-301 gene therapy
This long-term follow-up study monitors people with sickle cell disease or transfusion-dependent beta-thalassemia who have already received the gene-editing therapy EDIT-301. It helps researchers understand how safe and effective the treatment is over time.
New York, New YorkAges 12–50 - NCT04628585Enrolling by invitation
Follow-up for people with sickle cell treated with gene therapy
This study is a long-term follow-up for people who already received gene therapy for sickle cell disease in a specific sponsor’s clinical trial. It helps researchers watch for long-term safety and outcomes over time.
New Hyde Park, New YorkAges 2–53 - NCT04208529Enrolling by invitationPhase 3
Long-term follow-up after receiving CTX001 infusion
This study follows people for a long time after they received CTX001 in an earlier (parent) study. It helps researchers learn about long-term safety and outcomes of the treatment.
New York, New YorkAges 2 years+ - NCT04398628Recruiting
Study of non-cancer blood disorders in people with bleeding or clotting
This study follows people with inherited or acquired non-cancer blood disorders to better understand symptoms, causes, and how different treatments work over time. You may be placed into a disorder-specific group, depending on your diagnosis and testing results.
Buffalo, New YorkAges Any age - NCT05431088RecruitingPhase 2/Phase 3
Study of osivelotor for sickle cell disease
This study tests an investigational medicine called osivelotor for people with sickle cell disease (SCD). The goal is to see if it can reduce pain crises and improve overall health. It is for adults and adolescents aged 12 and older.
New York, New YorkAges 12 years+ - NCT07373639Recruiting
Long-term follow-up after BEAM-101 treatment
This study is for people who have already received BEAM-101 in a previous study. It simply follows them over time to track their health and any long-term effects.
New York, New YorkAges 14–37
Sickle Cell Disease trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting sickle cell disease studies listed above.
- Columbia University Irving Medical Center · 8 studies
- Jacobi Medical Center · 5 studies
- Montefiore Medical Center · 4 studies
- Weill Cornell Medicine · 3 studies
- Children's Hospital at Montefiore · 2 studies
- Cohen Children's Medical Center · 2 studies
- Icahn School of Medicine at Mount Sinai · 2 studies
- Morgan Stanley Children's Hospital · 2 studies
What taking part in a sickle cell disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Sickle Cell Disease trials in other states
Common questions
- Are there sickle cell disease clinical trials in New York?
- Yes. We're currently tracking 28 recruiting sickle cell disease studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a sickle cell disease study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a sickle cell disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New sickle cell disease studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.